NeuBase Therapeutics to Participate in Upcoming Investor Conferences in May 2021
May 14, 2021 12:31 ET
|
NeuBase Therapeutics, Inc.
RBC Capital Markets Virtual Global Healthcare Conference Fireside Chat at 11:30 a.m. ET on May 19 Oppenheimer Rare & Orphan Disease Summit presentation on May 21 PITTSBURGH, May 14, 2021 ...
NeuBase Therapeutics Reports Financial Results for the Second Quarter of Fiscal Year 2021
May 13, 2021 16:05 ET
|
NeuBase Therapeutics, Inc.
Extended cash runway into CY2023 following completion of an equity financing from leading healthcare investors generating $42.6 million in net proceeds; supports advancing the Company’s lead program...
NeuBase Therapeutics Appoints Gerald J. McDougall to Board of Directors
May 12, 2021 09:00 ET
|
NeuBase Therapeutics, Inc.
Professional dealmaker operating across the healthcare continuum to bring together key partners to translate scientific breakthroughs into commercial applications for the benefit of patients and...
NeuBase Therapeutics to Present at the B. Riley Securities’ Virtual Neuroscience Conference
April 27, 2021 08:00 ET
|
NeuBase Therapeutics, Inc.
PITTSBURGH, April 27, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase”), a biotechnology company accelerating the genetic revolution with a new class of precision...
NeuBase Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
April 26, 2021 16:01 ET
|
NeuBase Therapeutics, Inc.
PITTSBURGH, April 26, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE), (“NeuBase”), a biotechnology company accelerating the genetic revolution with a new class of precision...
NeuBase Therapeutics Announces Pricing of $40 Million Public Offering of Common Stock
April 22, 2021 09:07 ET
|
NeuBase Therapeutics, Inc.
PITTSBURGH, April 22, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase”), a biotechnology company accelerating the genetic revolution with a new class of precision...
NeuBase Therapeutics Announces Proposed Public Offering of Common Stock
April 21, 2021 16:01 ET
|
NeuBase Therapeutics, Inc.
PITTSBURGH, April 21, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase”), a biotechnology company accelerating the genetic revolution with a new class of precision...
NeuBase Therapeutics to Host a Virtual R&D Day on June 8th to Provide Updates on the Drug Development Pipeline Targeting Genetic Diseases
April 08, 2021 08:00 ET
|
NeuBase Therapeutics, Inc.
PITTSBURGH, April 08, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology company accelerating the genetic revolution with a new class of...
NeuBase Therapeutics to Present at the 2021 Muscular Dystrophy Association Virtual Clinical & Scientific Conference
March 16, 2021 08:00 ET
|
NeuBase Therapeutics, Inc.
PITTSBURGH, March 16, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ: NBSE) (“NeuBase” or the “Company”), a biotechnology company accelerating the genetic revolution using a new class...
NeuBase Therapeutics to Present at Upcoming Investor Conferences in March 2021
March 09, 2021 07:00 ET
|
NeuBase Therapeutics, Inc.
PITTSBURGH, March 09, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ: NBSE) (“NeuBase” or the “Company”), a biotechnology company accelerating the genetic revolution using a new class...